Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT02025010
Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer
- NCT02025010 ↗
- Completed
- Dana-Farber Cancer Institute
- Focused
We haven't built an HCP commentary report on NCT02025010 (abiraterone in castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02025010 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- abiraterone acetate
- Arms
- abiraterone acetate · Experimental
- Enrollment
- 60
- Primary outcomes
- Number of Participants With Toxicities That Required the Addition of Prednisone to Manage Symptoms of Persistent or Severe Mineralocorticoid Excess
- Sponsor
- Dana-Farber Cancer Institute with Janssen Research & Development, LLC
- Start
- Jan 27, 2014
- Primary completion
- Dec 2021
- Results posted
- Yes
- Registry record
- NCT02025010 · updated Apr 15, 2025
Publications
linked from the registry- Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW, Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol. 2021 Sep 10;39(26):2926-2937. doi: 10.1200/JCO.21.00169. Epub 2021 Jul 1. PubMed 34197212